These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

479 related items for PubMed ID: 19559929

  • 1. Platelet-derived growth factor expression correlates with tumor grade and proliferative activity in human oligodendrogliomas.
    Majumdar K, Radotra BD, Vasishta RK, Pathak A.
    Surg Neurol; 2009 Jul; 72(1):54-60. PubMed ID: 19559929
    [Abstract] [Full Text] [Related]

  • 2. Cyclooxygenase-2 in oligodendroglial neoplasms.
    Castilla EA, Prayson RA, Kanner AA, Rybicki LA, Tubbs RR, Vogelbaum MA, Barnett GH.
    Cancer; 2003 Oct 01; 98(7):1465-72. PubMed ID: 14508834
    [Abstract] [Full Text] [Related]

  • 3. Oligodendrogliomas in relation to astrocytes differentiation. Clinicopathologic and immunohistochemical study.
    Tena-Suck ML, Moreno-Jiménez S, Alonso M, Aguirre-Crux L, Sánchez A.
    Ann Diagn Pathol; 2008 Oct 01; 12(5):313-21. PubMed ID: 18774492
    [Abstract] [Full Text] [Related]

  • 4. MIB-1 labeling index in astrocytic tumors--a clinicopathologic study.
    Neder L, Colli BO, Machado HR, Carlotti CG, Santos AC, Chimelli L.
    Clin Neuropathol; 2004 Oct 01; 23(6):262-70. PubMed ID: 15584210
    [Abstract] [Full Text] [Related]

  • 5. The expression of cell cycle regulatory proteins in oligodendroglial tumors.
    Kamiya M, Nakazato Y.
    Clin Neuropathol; 2002 Oct 01; 21(2):52-65. PubMed ID: 12005253
    [Abstract] [Full Text] [Related]

  • 6. Caveolin-1 expression is variably displayed in astroglial-derived tumors and absent in oligodendrogliomas: concrete premises for a new reliable diagnostic marker in gliomas.
    Cassoni P, Senetta R, Castellano I, Ortolan E, Bosco M, Magnani I, Ducati A.
    Am J Surg Pathol; 2007 May 01; 31(5):760-9. PubMed ID: 17460461
    [Abstract] [Full Text] [Related]

  • 7. Pathobiology of pituitary adenomas and carcinomas.
    Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, Yapicier O, Young WF, Meyer FB, Kuroki T, Riehle DL, Laws ER.
    Neurosurgery; 2006 Aug 01; 59(2):341-53; discussion 341-53. PubMed ID: 16883174
    [Abstract] [Full Text] [Related]

  • 8. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops.
    Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, Westermark B, Nistér M.
    Cancer Res; 1992 Jun 01; 52(11):3213-9. PubMed ID: 1317261
    [Abstract] [Full Text] [Related]

  • 9. Oligodendroglial tumors with marked desmoplasia: clinicopathologic and molecular features of 7 cases.
    Jentoft M, Giannini C, Rossi S, Mota R, Jenkins RB, Rodriguez FJ.
    Am J Surg Pathol; 2011 Jun 01; 35(6):845-52. PubMed ID: 21552114
    [Abstract] [Full Text] [Related]

  • 10. Expression of growth factors and their receptors in human osteosarcomas. Immunohistochemical detection of epidermal growth factor, platelet-derived growth factor and their receptors: its correlation with proliferating activities and p53 expression.
    Oda Y, Wehrmann B, Radig K, Walter H, Röse I, Neumann W, Roessner A.
    Gen Diagn Pathol; 1995 Oct 01; 141(2):97-103. PubMed ID: 8548600
    [Abstract] [Full Text] [Related]

  • 11. Caveolin-1 expression in diffuse gliomas: correlation with the proliferation index, epidermal growth factor receptor, p53, and 1p/19q status.
    Barresi V, Buttarelli FR, Vitarelli EE, Arcella A, Antonelli M, Giangaspero F.
    Hum Pathol; 2009 Dec 01; 40(12):1738-46. PubMed ID: 19716156
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of malignant features in oligodendroglial tumors.
    Saito A, Nakazato Y.
    Clin Neuropathol; 1999 Dec 01; 18(2):61-73. PubMed ID: 10192700
    [Abstract] [Full Text] [Related]

  • 13. Immunohistochemical analysis of platelet-derived growth factor and its receptors in soft tissue malignant fibrous histiocytoma.
    Yamamoto T, Akisue T, Marui T, Fujita I, Matsumoto K, Kawamoto T, Hitora T, Nakatani T, Nagira K, Kurosaka M.
    Anticancer Res; 2003 Dec 01; 23(5b):4325-8. PubMed ID: 14666646
    [Abstract] [Full Text] [Related]

  • 14. Prognostic and survival-related factors in patients with well-differentiated oligodendrogliomas.
    Maiuri F, Del Basso De Caro ML, Iaconetta G, Peca C, Esposito M, de Divitiis E.
    Zentralbl Neurochir; 2006 Nov 01; 67(4):204-9. PubMed ID: 17106834
    [Abstract] [Full Text] [Related]

  • 15. Clinicopathologic study of forty-four histologically pure supratentorial oligodendrogliomas.
    Prayson RA, Mohan DS, Song P, Suh JH.
    Ann Diagn Pathol; 2000 Aug 01; 4(4):218-27. PubMed ID: 10982299
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype.
    Rushing EJ, Brown DF, Hladik CL, Risser RC, Mickey BE, White CL.
    Mod Pathol; 1998 May 01; 11(5):464-70. PubMed ID: 9619600
    [Abstract] [Full Text] [Related]

  • 19. EGF-R and PDGF-R, but not bcl-2, overexpression predict overall survival in patients with low-grade astrocytomas.
    Varela M, Ranuncolo SM, Morand A, Lastiri J, De Kier Joffé EB, Puricelli LI, Pallotta MG.
    J Surg Oncol; 2004 Apr 01; 86(1):34-40. PubMed ID: 15048678
    [Abstract] [Full Text] [Related]

  • 20. Expression of platelet-derived growth factor-AA and platelet-derived growth factor-alpha receptor in ameloblastomas.
    Sulzbacher I, Wick N, Pichlhofer B, Mazal PR.
    J Oral Pathol Med; 2008 Apr 01; 37(4):235-40. PubMed ID: 18284546
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.